Sernova Biotherapeutics Inc
PSH0
Company Profile
Business description
Sernova Biotherapeutics Inc is a clinical-stage biotechnology company focused on advancing regenerative medicine for the treatment of chronic diseases. The Company's primary asset is its proprietary Cell Pouch, a bio-hybrid organ system designed to enhance the delivery of cell therapy by replicating natural body functions. The Cell Pouch creates a vascularized, organ-like environment that promotes the longevity and functionality of therapeutic cells and ensures containment for retrievability.
Contact
RPO Central Parkway
PO Box 29592
MississaugaONL5A 4H2
CANT: +1 877 299-4603
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 October 2026
Employees
8
Stocks News & Analysis
stocks
Ahead of earnings, is Nvidia a buy, a sell, or fairly valued?
Amid robust demand for semis, watch for any impact of in-house built chips and whether the supply chain is on track.
stocks
Higher interest rates boost earnings for ASX real estate platform
Interest rates are driving a spike in property listings.
stocks
After earnings, is Palantir a buy, a sell, or fairly valued?
With uncertainty regarding its total addressable market and competitive threats, here’s what we think of Palantir stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,880.70 | 7.70 | 0.09% |
| CAC 40 | 7,979.92 | 76.46 | -0.95% |
| DAX 40 | 23,954.93 | 395.35 | -1.62% |
| Dow JONES (US) | 49,760.56 | 56.09 | 0.11% |
| FTSE 100 | 10,265.32 | 4.11 | -0.04% |
| HKSE | 26,348.15 | 0.24 | 0.00% |
| NASDAQ | 26,088.20 | 185.92 | -0.71% |
| Nikkei 225 | 63,272.11 | 529.54 | 0.84% |
| NZX 50 Index | 13,063.06 | 17.27 | -0.13% |
| S&P 500 | 7,400.96 | 11.88 | -0.16% |
| S&P/ASX 200 | 8,630.40 | 0.60 | -0.01% |
| SSE Composite Index | 4,241.93 | 27.44 | 0.65% |